Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.20%
1,108.23
-2.24
-0.20%
—1,110.471,107.751,111.341,093.81——
SIXC
Communications
SIXC
Communications
SIXC
+0.26%
605.63
+1.56
+0.26%
—604.07604.07606.04600.91——
SIXE
Energy
SIXE
Energy
SIXE
+0.70%
1,209.95
+8.46
+0.70%
—1,201.491,205.921,215.311,201.02——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.40%
1,758.23
-7.07
-0.40%
—1,765.301,764.031,764.031,736.40——
SIXM
Financials
SIXM
Financials
SIXM
+0.72%
634.94
+4.52
+0.72%
—630.42630.34636.69626.03——
SIXR
Staples
SIXR
Staples
SIXR
+1.30%
852.37
+10.92
+1.30%
—841.45843.60858.11840.11——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.01%
218.85
+0.020
+0.01%
—218.83218.83219.32217.33——
SIXT
Technology
SIXT
Technology
SIXT
-1.50%
3,528.49
-53.74
-1.50%
—3,582.233,550.603,562.623,447.78——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.10%
914.82
+0.93
+0.10%
—913.89912.75918.12906.67——
SIXV
Health care
SIXV
Health care
SIXV
+1.93%
1,472.27
+27.94
+1.93%
—1,444.331,446.871,480.741,446.30——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.93%
2,390.61
-22.35
-0.93%
—2,412.962,403.992,411.412,373.90——
CRNX:NASDAQ
Crinetics Pharmaceuticals Inc
$36.91
+0.98%
(+0.36) 1D
$36.91
0.00% (0.00)
After hours
Closed: May 12, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRNX...
Open
$36.00
High
$37.55
Low
$35.94
Mkt. cap
3.89B
Avg. vol.
1.28M
Volume
13.00
52-wk high
$57.99
52-wk low
$25.83
EPS
-$5.13
Beta
0.28
Shares outstanding
105.44M
No. of employees
594
News stories
From sources across the web
Profile
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018. Wikipedia
About Crinetics Pharmaceuticals Inc
CEO-
Employees594
FoundedNov 18, 2008
Headquarters-
SectorPharmaceutical industry
Websitecrinetics.com
Last report
May 7, 2026
Fiscal Period
Q1 2026
EPS / Est. (USD)
-$1.23 / -$1.23
-0.07%miss
Revenue / Est. (USD)
10.73M / 8.52M
+26.03%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.03M
143.00K
6.16M
10.73M
Cost of goods sold
80.30M
90.46M
86.13M
100.28M
Cost of revenue
80.30M
90.46M
86.13M
100.28M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
49.84M
52.26M
53.70M
50.83M
Operating expense
49.84M
52.26M
53.70M
50.83M
Total operating expenses
130.14M
142.73M
139.83M
151.11M
Operating income
-129.11M
-142.59M
-133.67M
-140.38M
Other non operating income
20.00K
-49.00K
-125.00K
-131.00K
EBT including unusual items
-115.64M
-130.09M
-122.64M
-127.84M
EBT excluding unusual items
-115.64M
-130.09M
-122.64M
-127.84M
Income tax expense
-
-
180.00K
-
Effective tax rate
-
-
-0.15%
-
Other operating expenses
-
-
-
-
Net income
-115.64M
-130.09M
-122.82M
-127.84M
Net profit margin
-11,216.00%
-90,972.73%
-1,993.43%
-1,191.03%
Earnings per share
-1.23
-1.38
-1.29
-1.23
Interest and investment income
13.46M
12.54M
11.16M
12.66M
Interest expense
-
-
-
-
Net interest expenses
13.46M
12.54M
11.16M
12.66M
Depreciation and amortization charges
-
-
-
-
EBITDA
-128.15M
-141.57M
-132.67M
-139.22M
Gain or loss from assets sale
23.00K
-
8.00K
20.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer